Literature DB >> 23071238

Epilogue: the peril and the promise of comparative effectiveness research in oncology.

Gary H Lyman1, Mark Levine.   

Abstract

Mesh：

Year:  2012        PMID： 23071238     DOI： 10.1200/JCO.2012.45.9800

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer.

Authors:  Nikki M Carroll; Thomas Delate; Alex Menter; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Elizabeth T Loggers; Debra P Ritzwoller
Journal:  J Oncol Pract       Date:  2015-06-09       Impact factor: 3.840

2.  Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop.

Authors:  Grace L Smith; Patricia A Ganz; Justin E Bekelman; Steven J Chmura; James J Dignam; Jason A Efstathiou; Reshma Jagsi; Peter A Johnstone; Michael L Steinberg; Stephen B Williams; James B Yu; Anthony L Zietman; Ralph R Weichselbaum; Ya-Chen Tina Shih
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-08       Impact factor: 7.038
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.